Mizuho reissued their buy rating on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a research report released on Monday. The firm currently has a $53.00 price target on the stock.

A number of other analysts have also recently commented on PCRX. Cowen and Company reiterated a hold rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 2nd. BidaskClub cut shares of Pacira Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, August 2nd. HC Wainwright set a $59.00 target price on shares of Pacira Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 3rd. BMO Capital Markets lowered their target price on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a market perform rating for the company in a research note on Thursday, August 3rd. Finally, Royal Bank Of Canada set a $58.00 target price on shares of Pacira Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, June 27th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $53.31.

Shares of Pacira Pharmaceuticals (PCRX) traded up 0.13% on Monday, reaching $39.40. 22,895 shares of the company were exchanged. The firm’s 50 day moving average price is $36.91 and its 200 day moving average price is $44.24. The stock’s market capitalization is $1.59 billion. Pacira Pharmaceuticals has a 52 week low of $29.95 and a 52 week high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The company had revenue of $70.90 million during the quarter, compared to analyst estimates of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the business earned $0.21 earnings per share. Equities research analysts anticipate that Pacira Pharmaceuticals will post ($0.17) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Pacira Pharmaceuticals, Inc. (PCRX) Earns “Buy” Rating from Mizuho” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/28/pacira-pharmaceuticals-inc-pcrx-earns-buy-rating-from-mizuho-2.html.

In other news, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total transaction of $37,740.60. Following the completion of the transaction, the director now directly owns 3,518 shares of the company’s stock, valued at approximately $127,175.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the transaction, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at $783,216. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,390 shares of company stock valued at $1,215,480. Insiders own 6.60% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio purchased a new position in shares of Pacira Pharmaceuticals during the 2nd quarter valued at approximately $1,782,000. Ameritas Investment Partners Inc. increased its holdings in shares of Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Pacira Pharmaceuticals by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,307 shares of the company’s stock valued at $1,446,000 after purchasing an additional 1,872 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Pacira Pharmaceuticals during the 2nd quarter valued at approximately $572,000. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after purchasing an additional 1,752 shares in the last quarter.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.